Results 41 to 50 of about 4,520 (170)

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Ondansetron in a Paxlovid Intolerant Man

Austin Journal of Clinical Case Reports, 2022
A symptomatic 22-year-old man, unvaccinated and living with high-risk elder parents, was prescribed nirmatrelvir/ritonavir (Paxlovid®) after testing positive for COVID-19. The patient developed persistent moderate to severe nausea after the first dose, progressing to severe nausea and several vomiting episodes after the second dose.
LG, Cubeddu, TM, Dalley, LX, Cubeddu
openaire   +1 more source

The pivotal role of β‐lactone stereochemistry in the development of SARS‐CoV‐2 Mpro inhibitors

Protein Science, Volume 35, Issue 7, July 2026.
Abstract From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides ...
Katarzyna Świderek, Vicent Moliner
wiley   +1 more source

Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study

BMC Medicine
Background Paxlovid has been shown to be effective in reducing mortality and hospitalization rates in patients with coronavirus disease 2019 (COVID-19).
Weijie Wang, Yu-Hsun Wang, Ching-Hua Huang, Tsung-Hsueh Hsieh, Gema Hernández Ibarburu, James Cheng-Chung Wei   +5 more
doaj   +1 more source

Structural analysis of the flexibility of the Ubl2 domain within the papain‐like protease of SARS‐CoV‐2

Acta Crystallographica Section F, Volume 82, Issue 6, Page 222-230, June 2026.
The ubiquitin‐like domain 2 (Ubl2) of the SARS‐CoV‐2 virus is necessary for the stability and catalytic efficiency of its papain‐like protease (PLpro). Our crystallographic study reveals that the Ubl2 domain exhibits notable flexibility and can adopt a conformation that places itself away from the PLpro catalytic domain, representing a new conformation
Gian Luca Freiherr von Scholley, Martina Schaefer, Mark D. Tully, Marc-Andre Hograindleur, Montserrat Soler-López, Roman C. Hillig, Christoph Mueller-Dieckmann, Eaazhisai Kandiah   +7 more
wiley   +1 more source

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study

BMC Infectious Diseases
Purpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients.
Kaican Zong, Li Xu, Chun Luo, Chen Luo, Bin Liu, Jiacheng Chen, Huizi Wu, Zhiqiang Liu, Rongjuan Zhuang, Shuliang Guo   +9 more
doaj   +1 more source

Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report

Medicine Advances, 2023
The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we
Qiang Li, Yibo He, Jin Liu, Xiaozhao Lu, Ziyou Zhou, Yu Kang, Wanying Wu, Jielan Wu, Feng Wang, Yinghao Sun, Wei Wang, Chengyi Hui, Wenting Wei, Miaoyun Wen, Jingjing Chen, Yong Liu   +15 more
doaj   +1 more source